Sign in

    Brian Gagnon

    Senior Partner and Portfolio Manager at Gagnon Securities

    Brian Gagnon is a Senior Partner and Portfolio Manager at Gagnon Securities LLC, where he specializes in discretionary equity portfolio management with a generalist approach spanning multiple sectors. As a senior analyst and advisor, he actively manages client portfolios invested across a range of public companies, overseeing holdings that as of August 2025 totaled nearly $492 million in market value with a disciplined track record reflected by low portfolio turnover and long average holding periods. Brian has been with Gagnon Securities for over two decades, advancing to a leadership role as part of a team recognized for thorough research and risk mitigation, although notable public rankings or individual performance figures are not disclosed. He is a registered representative, operating under FINRA and SEC regulations, and holds relevant securities licenses as required for his advisory and portfolio management responsibilities.

    Brian Gagnon's questions to Profound Medical (PROF) leadership

    Brian Gagnon's questions to Profound Medical (PROF) leadership • Q2 2024

    Question

    Brian Gagnon of Gagnon Securities inquired about the current number of procedures per day performed by top TULSA users and their future expectations with reimbursement. He also asked for details on the new 0.55T interventional MRI systems and sought confirmation that radical prostatectomies are unprofitable for hospitals on CMS patients, which would benefit TULSA.

    Answer

    CEO Arun Menawat and COO Mathieu Burtnyk stated that roughly 25% of sites are already performing 3-4 procedures per day, a number expected to increase with the new AI modules. Menawat detailed the advantages of the new 0.55T MRIs, including lower weight, smaller footprint, and reduced shielding costs, making them ideal for office or ASC settings. He confirmed that robotic prostatectomy is often a loss-leader for hospitals on Medicare patients, and Profound believes TULSA can offer a break-even or profitable alternative in that setting.

    Ask Fintool Equity Research AI